Definitions of time to and duration of response, and the time to initial and peak response for different ITP treatments*
| Time to response | From start of treatment until either complete response or response | ||
| Duration of response | Time from complete response or response until loss of complete response or response Measured as the proportion of the cumulative time spent in complete response or response during the period under examination as well as the total time observed from which the proportion is derived | ||
| Expected time to response | Treatment type | Initial response, days | Peak response, days |
| Anti-D | 1-3 | 3-7 | |
| Azathioprine | 30-90 | 30-180 | |
| Danazol | 14-90 | 28-180 | |
| Dexamethasone | 2-14 | 4-28 | |
| Eltrombopag | 7-28 | 14-90 | |
| IVIg | 1-3 | 2-7 | |
| Prednisone | 4-14 | 7-28 | |
| Rituximab | 7-56 | 14-180 | |
| Romiplostim | 5-14 | 14-60 | |
| Splenectomy | 1-56 | 7-56 | |
| Vinblastine | 7-14 | 7-42 | |
| Vincristine | 7-14 | 7-42 | |
| Time to response | From start of treatment until either complete response or response | ||
| Duration of response | Time from complete response or response until loss of complete response or response Measured as the proportion of the cumulative time spent in complete response or response during the period under examination as well as the total time observed from which the proportion is derived | ||
| Expected time to response | Treatment type | Initial response, days | Peak response, days |
| Anti-D | 1-3 | 3-7 | |
| Azathioprine | 30-90 | 30-180 | |
| Danazol | 14-90 | 28-180 | |
| Dexamethasone | 2-14 | 4-28 | |
| Eltrombopag | 7-28 | 14-90 | |
| IVIg | 1-3 | 2-7 | |
| Prednisone | 4-14 | 7-28 | |
| Rituximab | 7-56 | 14-180 | |
| Romiplostim | 5-14 | 14-60 | |
| Splenectomy | 1-56 | 7-56 | |
| Vinblastine | 7-14 | 7-42 | |
| Vincristine | 7-14 | 7-42 | |
Adapted from the International Working Group.7